PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Ezetimibe - Lipid modification
PAD Profile : Ezetimibe - Lipid modification
Keywords :
primary hypercholesterolaemia, high cholesterol, raised cholesterol, familial hypercholesterolaemia, lipid-lowering, lipid lowering
Brand Names Include :
Ezetrol
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Atorvastatin
- Rosuvastatin calcium
- Simvastatin
- Pravastatin sodium
- Fluvastatin sodium
- Evolocumab
- Alirocumab
- Fenofibrate
- Bezafibrate
- Ciprofibrate
- Gemfibrozil
- Colesevelam hydrochloride
- Colestyramine
- Bempedoic acid
- Inclisiran
- Icosapent
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
03 September 2014
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
People with primary hypercholesterolaemia should be considered for ezetimibe treatment in line with TA385 (formerly TA132 superceded by TA385 in Feb 2016) - see below
Associated BNF Codes
02. Cardiovascular System
02.12.00. Lipid-regulating drugs